ClinicalTrials.gg
Status unknownNCT01360164Updated Nov 28, 2012

Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia

A Phase 1/2 interventional study of human umbilical cord mesenchymal stem cells in Hereditary Ataxia, sponsored by Shenzhen Beike Bio-Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-11-28.

Sponsored by Shenzhen Beike Bio-Technology Co., Ltd. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2012), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Spinocerebellar Degenerations with a site in China — 7 open to participants now, 7 under way, 2 of them phase 3. Spinocerebellar Degenerations · China.

Started
2010
the only one that year
Phase 1/2
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
1 of 10
Shenzhen Beike Bio-Technology Co., Ltd.

Among the 10 studies in Spinocerebellar Degenerations with a site in China, this one is the only one that started in 2010, is the only one in phase 1/2, and was the 1st registered.

Spinocerebellar Degenerations

49 studies on the registry are indexed under Spinocerebellar Degenerations; 15 are open to participants now.

Browse Spinocerebellar Degenerations studies →

Open to participants now

7 of the 10 studies in Spinocerebellar Degenerations with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 9 Spinocerebellar Degenerations studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Spinocerebellar Degenerations with a site in China, or all of them as a file.
02

Study summary

The Hereditary Ataxias are a group of genetic disorders characterized by slowly progressive incoordination of gait and often associated with poor coordination of hands, speech, and eye movements. Current treatments for Hereditary Ataxias are mainly pharmacological, rehabilitative, or psychological treatments,while no effective treatment available. Stem Cell therapy is a novel and promising therapeutic strategy for Hereditary Ataxias treatment. In this study, the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells transplantation will be evaluated in patients with Hereditary Ataxias.

Read the detailed description

This Study is designed to evaluate the the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells transplantation in patients with Hereditary Ataxias.

03

Conditions studied

  • Hereditary Ataxia

Keywords

  • Human Umbilical Cord Mesenchymal Stem Cells
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 16-65 years.
  • Harding Diagnosis of SCAs, gene type confirmed.
  • Candidates who did not receive any stem cell therapy in past 6months.
  • sign the consent form and follow the clinic trail procedure.

Exclusion criteria

Exclusion Criteria:

  • Cardiac insufficiency; Renal insufficiency; hepatic insufficiency; Total higher than 1.5 times of value; /ALT higher than 2.5 times of upper limit of normal value;
  • Routine Blood Test: WBC count \<3.0×109/ L; count \<5×109/L ; or \<100g/L;
  • Combined Pneumonia or other Severe systemic bacteria infection;
  • Severe drug allergic history or anaphylaxis to 2 or more food or medicine;
  • Other brain organic disease (eg. Brain cancer);
  • +, Tumor Markers + ;
  • Severe psychotic patients, cognitive dysfunction, or can not understand or sign the Consent Form;
  • Other severe systemic or organic disease;
  • Uncontrolled hypertension,blood pressure≥180mmHg/110 mmHg after treatment;
  • Pregnancy;
  • Enrollment in other trials in the last 3 months;
  • Other criteria the investigator consider improper for inclusion.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Human umbilical cord mesenchymal stem cells transplantation

    Participants will be given umbilical cord mesenchymal stem cells transplantation with a 1 year follow-up.

    Biological: human umbilical cord mesenchymal stem cells

Interventions

06

What researchers measure

Primary outcomes

  1. scores of International Cooperative Ataxia Rating Scale (ICARS) scale and Berg Scale

    Time frame: 1 year after treatment

  2. the volume of Cerebellum of Brain Magnetic Resonance Imaging (MRI) Scan

    Time frame: 1 year after treatment

Secondary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    Time frame: 1 year after treatment

  2. Number of Participants with Serious Adverse Events as a Measure of Safety and Tolerability

    Time frame: 1 year after treatment

07

Study locations

1 of 1 sites recruiting
  • Nanjing University Medical College Affiliated Drum Tower Hospital
    Nanjing, Jiangsu, China
    Recruiting
08

References and documents

Publications

  • Jin JL, Liu Z, Lu ZJ, Guan DN, Wang C, Chen ZB, Zhang J, Zhang WY, Wu JY, Xu Y. Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia. Curr Neurovasc Res. 2013 Feb;10(1):11-20. doi: 10.2174/156720213804805936. PubMed 23151076 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Dec 2012 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2011
First posted
May 25, 2011
Start
Jan 2010
Primary completionEst.
Dec 2012
CompletionEst.
Dec 2013
Last update
Nov 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01360164
Lead sponsor
Shenzhen Beike Bio-Technology Co., Ltd.
Collaborators
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Nanjing Brain Hospital of Nanjing University Medical School, Nanjing University Medical College Affiliated Wuxi Second Hospital, Xuzhou Medical University, The Second Hospital of Nanjing Medical University
Responsible party
Sponsor
First posted
May 25, 2011
Start date
Jan 2010
Primary completion
Dec 2012 (estimated)
Completion
Dec 2013 (estimated)
Last update
Nov 28, 2012

Study contacts

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion